Nguyen Timothy, Wong Elaine
Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA.
Consult Pharm. 2012 Jul;27(7):509-12. doi: 10.4140/TCP.n.2012.509.
Dabigatran is a novel oral direct thrombin inhibitor that has been shown to have beneficial outcomes in the prevention of thromboembolic stroke in patients with atrial fibrillation. Its advantages compared with warfarin may include decreased laboratory monitoring (e.g., international normalized ratio), minimal cytochrome P450 drug interactions, lack of dietary interactions, and faster onset of action. However, dabigatran is still associated with drug interactions, as will be reviewed through a patient case. Consultant pharmacists should carefully review a patient&s medication profile and evaluate the pros and cons of dabigatran therapy as its use becomes more prevalent.
达比加群是一种新型口服直接凝血酶抑制剂，已被证明在预防心房颤动患者血栓栓塞性卒中方面具有有益效果。与华法林相比，其优势可能包括减少实验室监测（如国际标准化比值）、最小化细胞色素P450药物相互作用、不存在饮食相互作用以及起效更快。然而，达比加群仍与药物相互作用有关，将通过一个患者病例进行回顾。随着达比加群的使用越来越普遍，临床药师应仔细审查患者的用药情况，并评估达比加群治疗的利弊。
